Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Geographic Atrophy Progression in AMD
NCT02684578Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Apr 2016
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of metformin in geographic atrophy (GA) (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Rate of Change in Area of Geographic Atrophy at 18 months. Started Apr 2016; status: completed.
02
Drugs
metformin
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT02684578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02684578.